Horizon Therapeutics announces $3.05bn acquisition of Viela Bio to expand rare disease pipeline
In a major move to strengthen its leadership in rare diseases, Horizon Therapeutics, an Irish biopharmaceutical company, has agreed to acquire Viela Bio, a US-based ... Read More
US biotech company Viela Bio bags Uplizna FDA approval for NMOSD
Uplizna FDA approval : US biotech company Viela Bio has secured approval from the US Food and Drug Administration (FDA) for Uplizna (inebilizumab-cdon) injection for ... Read More